||Neonatal Drug Therapy Manual
Disclaimer: Official controlled document is the CHEO and Ottawa Hospital online copy. It is the responsibility of user to ensure that any paper copy version is the same as the online version before use.
Carbonic anhydrase inhibitor
- To reduce the rate of cerebrospinal fluid production in hydrocephalus
- Treatment of metabolic alkalosis
- 25 mg/kg/day divided Q6H. Increase as needed by 25 mg/kg/day, to a maximum of 100 mg/kg/day divided Q6H
- Metabolic alkalosis:
- 5 mg/kg/dose every 6 to 8 hours
- Endocrine and metabolic: hypokalemia, metabolic acidosis
- Respiratory: hyperpnea
Parameters to Monitor:
- Head circumference
- Serum electrolytes, serum bicarbonate
- Acid-base balance
Reconstitution and Stability:
Taketomo CK, Hodding JH, Kraus DM. Pediatric Dosage Handbook 22nd Edition. Hudson: Lexi-Comp Inc.; 2015.
Andrews MG, Johnson PN, Lammers EM, Harrison DL, Miller JL. Acetazolamide in critically ill neonates and children with metabolic alkalosis. Ann Pharmacother. 2013;47(9):1130-1135.
Tam B, Chhay A, Yen L, Tesoriero L, Ramanathan R, Seri I, Friedlich PS. Acetazolamide for the management of chronic metabolic alkalosis in neonates and infants. Am J Ther. 2014;21(6):477-481
The information contained on this website is provided for informational purposes only, as a guide to assist physicians, nurses and other healthcare providers in deciding on the appropriate care required for a particular patient. At all times, physicians, nurses and other healthcare providers must exercise their independent clinical judgment, based on their knowledge, training and experience, taking into account the specific facts and circumstances of each patient, when deciding on the appropriate course of investigation and/or treatment to recommend in a particular clinical situation.
CHEO has made every effort to ensure that the information contained on this website is as current and accurate as possible. However, changes can occur due to ongoing research and the constant influx of new information. Where possible, hospitals and healthcare practitioners should verify the information before acting on it.
Reliance on any information in this website is at the user's own risk. CHEO is not responsible or liable for any harm, loss or other consequences from the use or misuse of the information on this website.